Standard of care (SOC) in fit, NPM1-mutated, FLT3-wildtype AML patients consists of intensive induction chemotherapy (commonly 7 + 3 regimens consisting of cytarabine plus an anthracycline/anthracenedione) with or without gemtuzumab ozogamicin (GO), followed by intermediate-dose cytarabine consolidation (IDAC). Here, NPM1 is linked to acute myeloid leukemia.